(ADMP) Market Cap $33 million--Cash $17 M --FDA Decision on Oct.31 for ZIMHI a treatment of opioid overdose which is a large market --company has already one marketed drug for the treatment of anaphylaxis launched early this year and partnered with Sandoz(Novartis) targeting a $1.5 BILLION Market .Current valuation of $33million is a PURE GIFT for this company a potential 10 bagger here . STRONG BUY SUPER AGGRESSIVE
Admamis Pharma (ADMP)
Market-Cap:$33 million
Cash: $17 million
Price: $0.54
Presentation
ir.adamispharmaceuticals.com
ZIMHI (naloxone) injection
Indication–Opioid Overdose
Addressable Market -$330 million
FDA action date Oct. 31, 2019
SYMJEPI (epinephrine) injection
Indication-Anaphylaxis
Addressable Market -$1.5 billion
Launched–January 2019
First products using patented, FDA-approved injection device
Both doses (0.3mg and 0.15mg) are FDA approved
Sandoz a division of Novartis –commercial partner in U.S.
Commercial deal terms –50% of net profits, upfront fee and potential performance-based milestone payments
Exploring potential licensing options for ex-US territories
Near-Term Target Milestones
FDA action date (PDUFA) of Oct. 31, 2019 on NDA for ZIMHI
Pursuing potential partnerships for SYMJEPI (ex-US) and ZIMHI product candidate
Continued launch of SYMJEPI in U.S. –retail and SYMJEPI low dose launches pending
Largest Shareholders :
Heights Capital...3.0M
683 Capital ...2.4M
The Vanguard ...1.8M
First Manhattan...1.4M
BlackRock...952.8K
Morgan Stanley...625.7K
Geode Capital...337.2K
Carlo (Dennis J)...292.3K
Moss (Ronald B)...285.0K
GSA Capital...139.6K |
